'\e628'
NEWS

Adenovirus rapid detection + diagnosis plan analysis

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2019-06-26
  • Views:4

(Summary description)

Adenovirus rapid detection + diagnosis plan analysis

(Summary description)

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2019-06-26
  • Views:4
Information

1. Background

Human adenovirus (HAdV) pneumonia (hereinafter referred to as adenovirus pneumonia) is one of the more serious types of community-acquired pneumonia in children. It occurs more frequently in children between 6 months and 5 years of age. Some children have severe clinical manifestations and extrapulmonary There are many complications, and chronic airway and lung diseases are susceptible to severe cases. It is one of the important causes of death and disability of infants and young children with pneumonia, which requires great attention.

DHAdV belongs to the mammalian adenovirus genus and is an unencapsulated double-stranded DNA virus. It was first discovered by Rowe et al in 1953. At least 90 genotypes have been found, which are divided into 7 subgenus A-G. HAdV infection can cause a variety of diseases, including pneumonia, bronchitis, cystitis, ocular conjunctivitis, gastrointestinal diseases, and encephalitis. Adenoviral pneumonia accounts for approximately 4% -10% of community-acquired pneumonia. A study in China summarized in children with severe pneumonia admitted to PICU from August 2016 to January 2019 and found that severe adenoviral pneumonia accounted for 6.03%.

HAdV types 3 and 7 are the most common serotypes in childhood adenoviral pneumonia, accounting for 50% of all adenovirus-induced lower respiratory tract infections. Among them, severe pneumonia is also common in types 3 and 7. In our country, adult patients with immune dysfunction reported that HAdV 55 is the main serotype of severe pneumonia with acute respiratory distress syndrome (ARDS). A multicenter adult and adolescent community-acquired pneumonia survey observed 5% (48/969) of adenoviral pneumonia and 43.8% (21/48) of HAdV 55. It is suggested that HAdV 55 has become the main serotype of adenoviral pneumonia in adult immunodeficiency patients, children and adolescents in China. HAdV infection is also one of the main causes of diarrhea in infants and young children, and its main infection serotypes are 40 and 41.

Generally, the inflammatory response of mild adenoviral pneumonia is not prominent, the white blood cell count is normal or decreased, the lymphocyte classification is the main type, and the CRP is normal. Severe adenoviral pneumonia has a strong inflammatory response. During the course of the disease, the white blood cell count is increased and neutrophils are the main part. CRP and PCT are increased. However, within 3 days of the onset of the disease, the white blood cell count and CRP are normal. Rise. Laboratory tests such as blood tests, biochemical tests, or markers of inflammation make it difficult to distinguish adenoviral pneumonia from bacterial pneumonia and mycoplasma pneumoniae pneumonia.

Although traditional virus isolation and serotyping are the gold standards for diagnosing adenoviruses, they are not suitable for early clinical diagnosis; although antigen detection methods can detect early in the onset of disease, the detection sensitivity is low. The Adenoviral Pneumonia Diagnosis and Treatment Guidelines for Children (2019 Edition) recommends the use of PCR method to detect adenovirus infection. PCR method is more sensitive than traditional virus culture and virus antigen detection, and the detection is accurate and fast.

 

2、 Product introduction

Jiangsu Hongwei Tesi Medical Technology Co., Ltd. and the Institute of Microbiology and Epidemiology of the Academy of Military Medical Sciences have developed a universal adenovirus nucleic acid detection kit (PCR-fluorescent probe method) and adenovirus 3, 7 and 55 nucleic acids Detection kit (PCR-fluorescent probe method). Adenovirus universal nucleic acid detection kit (PCR-fluorescent probe method) is mainly targeted at 10 types of 1, 2, 3, 4, 6, 7, 11, 14, 15, and 55. Adenovirus type 3, 7 and 55 nucleic acid detection kits (PCR-fluorescent probe method) are mainly targeted at the three main infection types 3, 7 and 55 that cause adenoviral pneumonia in children. The above kit is based on the fluorescence PCR detection technology, which can realize the universal type and 3, 7, 55 type detection of adenovirus infection within 1 hour, and provide auxiliary basis for early differential diagnosis of adenovirus infection.

2.1 Product Features:

High sensitivity: accurate detection down to 1copies / response.

High specificity: with other pathogens (such as influenza A virus, influenza B virus, respiratory syncytial virus, parainfluenza virus, rhinovirus, human metapneumovirus, etc.) or bacteria (streptococcus pneumoniae, Klebsiella pneumoniae) , Pseudomonas aeruginosa, Acinetobacter baumannii, Staphylococcus aureus, etc.) No cross-reactivity.

Accurate diagnosis: full coverage of general and main types, more accurate diagnosis

Strict quality control: The internal control of primers can fully monitor the experimental process and ensure the quality of the experiment.

Real-time amplification: You can observe the detection results in real time.

Easy operation: one-step loading and sample addition, requiring less professional ability of the operator.

Fast time: detection is completed within 1 h.

 

2.2 Detection process

 

腺病毒快速检测+确诊方案解析

 

2.3 Test results

腺病毒快速检测+确诊方案解析

Adenovirus Universal Nucleic Acid Detection Kit Minimum Detection Limit

(1-5, 104, 103, 102, 101, and 1copies / μL adenovirus universal plasmids, respectively)

 

腺病毒快速检测+确诊方案解析

Adenovirus universal nucleic acid detection kit test sample results

 

腺病毒快速检测+确诊方案解析

Adenovirus type 3, 7 and 55 nucleic acid detection kit detection limit (take adenovirus type 3 as an example)
 
(1-5, 104, 103, 102, 101, and 1copies / μL adenovirus type 3 plasmids, respectively)

 

腺病毒快速检测+确诊方案解析

Adenovirus type 3, 7 and 55 nucleic acid detection kit test positive control results

 

3. Company profile

Jiangsu Hongwei Tesi Pharmaceutical Technology Co., Ltd. was established in 2016 (hereinafter referred to as Jiangsu Hongwei), focusing on the development, production and sales of new detection technologies and new in vitro diagnostic reagents. At present, a GMP production workshop with an area of ​​4,000 square meters including three categories of molecules, immunity and POCT has been completed, and has passed ISO13485 quality system certification. Since the establishment of the company, it has independently established a platform for the detection of pathogenic microorganism metagenomes, a multi-target nucleic acid detection technology platform, an enzyme digestion probe extended isothermal rapid detection molecular platform and an immunofluorescence technology platform. Participated in three topics of the 13th Five-Year Plan for Infectious Diseases (R & D of 12 acute infectious disease detection technologies (2018ZX10732401-001-005), HBV pgRNA detection kit and protein liver cancer detection reagents (2018ZX10732202-003-002) and merger Research on Targeted Virus Enrichment Technology (2018ZX10301-101-004)). Jointly filed with other units to obtain 2 NMPA registration certificates. It has applied for six invention patents, and has developed more than 30 related products on the independent technology platform, including pathogens related to respiratory infections, pathogens related to reproductive tract infections, and pathogens related to bloodstream infections. More than 200 products have been completed so far.

Our development goal is to provide first-class medical products and services for human health, benefit society and employees.

 

4. References

[1] ROWE WP, HUEBNER RJ, GILMO RELK, et al. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture [J]. Proc Soc Exp Biol Med, 1953, 84 (3): 570-573.

[2] RuuskanenO, LahtiE, JenningsLC, et al. Viral pneumonia [J] .Lancet, 2011, 377 (9773): 1264-1275.

[3] LynchJP, KajonAE.Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention [J] .Semin Respir Crit Care Med, 2016, 37 (4): 586-602.

[4] LynchJP, KajonAE.Adenovirus: Epidemiology, Global Spread of Novel Serotypes, and Advances in Treatment and Prevention [J] .Semin Respir Crit Care Med, 2016, 37 (4): 586-602.

[5] Shi Jingyi, Wang Fei, Xu Tingting, et al. Discussion on the characteristics and treatment of severe adenoviral pneumonia in children intensive care unit [J] .Chinese Pediatric Emergency Medicine, 2019,26 (3): 190-194.

[6] SunB, HeH, WangZ, et al. Emergent severe acute respiratory distress syndrome caused by adenovirus type 55 in immunocompetent adults in 2013: a prospective observational study [J] .Crit Care, 2014, 18 (4): 456.

[7] CaoB, HuangGH, PuZH, et al. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia [J] .Chest, 2014, 145 (1): 79-86.

[8] Childhood Adenoviral Pneumonia Diagnosis and Treatment Specifications (2019 Edition)

 

5. Contact

Contact: Manager Feng

Phone: 0513-80562878

Zip code: 226400

Website: www.hongweitest.com

Company address: No. 888 Zhujiang Road, Digang Street, Rudong County, Jiangsu Province (Building 10, Life and Health Industrial Park, Rudong High-tech Zone)

Scan the QR code to read on your phone

logo

Accurate diagnosis, shaping a better life

Copyright © 2019 Jiangsu Macro micro-test Medical Technology Co., Ltd.  all rights reserved

苏ICP备18057655号  苏公网安备 32062302000215号

Power by:300.cn

WeChat public account

WeChat public account

Macro & Micro-Test

Jiangsu Address: No. 888 Zhujiang Road, Digang Street, Rudong County, Jiangsu Province (Building 10, Life and Health Industrial Park, High-tech Zone)
Phone:
86-513-80562880
Beijing Address: West side, 3rd floor, Building 2, No. 28 Yuhua Road, Airport Science Park, Shunyi District, Beijing
Phone:
86-10-80497001
Company email: jshwts@sina.com